On Friday, after market hours, Solara Active Pharma Science announced the successful completion of US FDA inspection at Solara Research Centre(SRC), Chennai with zero 483s inspectional observations.

Established in 2005, SRC is a state-of-the-art R&D centre with capabilities to develop niche products characterised by complex chemistry across the diverse therapeutic categories. The centre is equipped with high-end infrastructure with advanced analytical capabilities, strong IP assessment skills and global regulatory expertise. It is led by experienced technical leadership which has demonstrated significant strategic value for the customers and the partners. SRC is also an important pivot in Solara’s Contract Research and manufacturing services(CRAMS) vertical.

SRC was earlier inspected by USFDA as “Control Testing Laboratory” in December 2012 and August 2016.

The market is very happy with this news and the stock hit the 10% UC at Rs.300.95 the moment it opened for trading today morning.  Its 52-week high stands at Rs.403.85.